Spark has priced its cure for a rare form of blindness at $425,000 per eye. But rather than the science or the cost, pharma is buzzing over the company’s outcomes-based pricing model
Amazon’s ability to attract other employers makes its healthcare coalition very formidable, experts say
Vertex moves two cystic fibrosis drugs into Phase III trials; American Heart Association says breast cancer survivors have higher risk of cardiovascular disease; Blood test to predict Alzheimer’s shows promise.